MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression

MindBio Therapeutics Corp. reported promising data from its Phase 2a clinical trial, marking a key moment in the development of a treatment for depression with MB22001, a microdosing form of lysergic acid diethylamide (LSD) for at-home use. This trial, described as a world first, revealed a rapid and clinically significant reduction in depression symptoms in participants.

Over an 8-week period, the trial demonstrated an average reduction of 14.1 points in the Montgomery-Asberg Depression Rating Scale (MADRS), corresponding to a 60% decrease in depressive symptoms, and 53% of patients achieving complete remission. According to the results, MB22001 was found to be safe and well tolerated, with no treatment-related serious adverse events.

This achievement places MindBio at the forefront of biopharmaceutical companies, being the only organization in the world to conduct multiple authorized clinical trials for at-home use and manipulation of a psychedelic medication by patients in the community. The company has been collecting a considerable amount of data for over three years, aiming to develop a proprietary treatment model that is safe, effective, and adaptable as a first-line treatment for depression.